List of articles in "Drug" category - Page 162

Radium-223 (Ra-223) is an isotope of radium with an 11.4-day half-life in contrast to the common isotope radium-226 discovered by the Curies which has a 1601-year half-life. The principal use […]

Riociguat (BAY 63-2521 trade name Adempas) is a novel drug (by Bayer) that is a stimulator of soluble guanylate cyclase (sGC). Clinical trials have looked at riociguat as a new […]

WAY-100135 is a serotonergic drug of the phenylpiperazine family which is used in scientific research. It acts as potent 5-HT1A receptor antagonist and was originally believed to be highly selective […]

Adhyperforin is a phytochemical found in the members of the plant genus Hypericum including St. John’s Wort. It has a very similar pharmacological profile to hyperforin and acts as a […]

Amfonelic acid (AFA; WIN 25978) is a research chemical with highly selective dopaminergic stimulant and antibiotic properties which may also function as a nootropic.[citation needed]

SEP-227162 is an antidepressant developed by Harvard Chemistry Graduate Tyler W. Murlo of Sepracor which is currently in clinical trials. It acts as a serotonin-norepinephrine reuptake inhibitor. As of 1 […]

SEP-225289 is an antidepressant drug derived from the active enantiomer of sibutramine which was being developed by Sepracor. It is a so-called triple reuptake inhibitor (TRI).

DOV 102677 is a psychoactive drug being developed by Merck as an antidepressant and is currently in clinical trials. It is a so-called triple (re)uptake inhibitor (TUI) or serotonin-norepinephrine-dopamine reuptake […]

DOV 216303 is an antidepressant drug originally developed by DOV Pharmaceutical and now licensed to the larger pharmaceutical company Merck & Co. which is currently in clinical trials. It is […]

NS-2359 (GSK-372475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant but was discontinued in 2009 when phase II clinical trials turned up disappointing […]